A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is an open-label dose-titration study in Japanese Central Diabetes Insipidus (CDI) patients designed to demonstrate the efficacy and safety of orally-disintegrating tablet of desmopressin.

Condition or disease	Intervention/treatment	Phase
Central Diabetes Insipidus	Drug: Desmopressin Oral Melt; Drug: Desmopressin intranasal	Phase 3

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	20 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients
Study Start Date :	January 2011
Actual Primary Completion Date :	August 2011
Actual Study Completion Date :	August 2012

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm

Intervention/treatment

Experimental: Desmopressin; Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.

Drug: Desmopressin Oral Melt; Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.; Other Names: Minirin; FE992026 Drug: Desmopressin intranasal; Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Change from Baseline in 24-hour Urine Volume [ Time Frame: Day 0, Week 4 ]

Secondary Outcome Measures :

1. 24-hour urine volume (mL) [ Time Frame: Day 0, Week 4 ]
2. Hourly diuresis rate (mL/hr) [ Time Frame: Day 0, Week 4 ]
3. Urine osmolality (mOsm/kg) [ Time Frame: Day 0, Week 4 ]
4. Urine specific gravity (g/mL) [ Time Frame: Day 0, Week 4 ]
5. Percentage of participants within normal range for urinary output, urinary osmolality and urine specific gravity [ Time Frame: Day 0, Week 4 ]
6. Serum sodium level [ Time Frame: up to Month 13 ]
7. Participants with Adverse Events Summarized by Incidence and Severity [ Time Frame: up to Month 13 ]
   Includes abnormal lab values and vital signs

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	6 Years to 75 Years (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Participants must be documented to have Central Diabetes Insipidus (CDI) by at least two of the following four criteria (a-d):

  1. Failure to increase urine osmolality above 300 mOsm/kg during a period of fluid deprivation sufficient to raise plasma osmolality and sodium above the upper limit of normal level for the reference laboratory (usually 295 mOsm/kg and 148 mEq/l, respectively)
  2. Complete and continuous control of the DI by desmopressin therapy without "breakthrough" diuresis, hypernatremia, hyponatremia, or symptoms or signs of water intoxication.
  3. A deficient plasma vasopressin response to osmotic or non-osmotic stimulation.
  4. Absence of the posterior pituitary bright spot on T-1 weighted midsagittal magnetic resonance imaging (MRI) of the brain.
• Given written informed consent prior to any trial-related procedure is performed
• 24 hour urine volume (mL), urine osmolality (mOsm/kg), urine specific gravity, and serum sodium (mEq/L) maintained at a normal level by desmopressin nasal administration
• Outpatient
• The participant is, in the investigator's opinion, otherwise healthy
• Be willing and able to comply with the protocol requirements including restriction of water intake

Exclusion Criteria:

• Presence or a history of nephrogenic diabetes insipidus or diabetes mellitus
• Presence of uncorrected hypothyroidism, hypoadrenalism or hypogonadism
• Abnormalities or disease of the oral cavity that might affect the release and absorption of drug
• Unable to be placed on water-intake restriction starting from two hours before bedtime
• Presence of a hypothalamus abnormality leading to thirst disorder
• Evidence of hepatic, renal, cardiac, or pulmonary dysfunction
• Uncontrolled hypertension
• Treatment with another investigational product within the past 3 months
• Concurrent treatment with diuretics, chlorpropamide, tricyclic antidepressants, indomethacin, carbamazepine
• Alcohol dependency or drug abuse
• Breastfeeding, pregnant, or likely to become pregnant
• A mental condition, the lack of decision-making ability, dementia or a speech handicap
• Any other reason that the Investigator believes inappropriate

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Japan
Aichi Medical University
Nagakute, Aichi, Aichi, Japan
Nagoya University Hospital
Nagoya, Aichi, Japan
Toranomon Hospital
Minato, Tokyo, Japan
Osaka Saiseikai Nakatsu Hospital
Osaka, Japan
Saitama Medical Center Jichi Medical University
Saitama, Japan

Sponsors and Collaborators

Ferring Pharmaceuticals

Investigators

Study Director:	Clinical Development Support	Ferring Pharmaceuticals

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Arima H, Oiso Y, Juul KV, Nørgaard JP. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60(9):1085-94. Epub 2013 Jun 28.

Responsible Party:	Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT01280188 History of Changes
Other Study ID Numbers:	FE992026 CS43
First Posted:	January 20, 2011
Last Update Posted:	August 13, 2012
Last Verified:	August 2012

Keywords provided by Ferring Pharmaceuticals:

Diabetes

Additional relevant MeSH terms:

Diabetes Insipidus; Diabetes Insipidus, Neurogenic; Kidney Diseases; Urologic Diseases; Pituitary Diseases; Endocrine System Diseases	Deamino Arginine Vasopressin; Hemostatics; Coagulants; Antidiuretic Agents; Natriuretic Agents; Physiological Effects of Drugs